FDA Brief

Warning letters Food

FDA warning letter to

Holistic Healer & Wellness Center, Inc.

High riskIssued Sep 7, 2021Posted Sep 9, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA and FTC warned Holistic Healer & Wellness Center that Diabalance Diabetes Supplement claims make it an unapproved new drug.

What happened

FDA reviewed the company’s website in August 2021 and found it took orders for Diabalance Diabetes Supplement. FDA said website claims that the product helps balance blood sugar and treat diabetes make it a drug intended to treat disease, an unapproved new drug, and misbranded for lacking adequate directions. FTC also reviewed the website in August 2021 and said the diabetes treatment claims may lack competent and reliable scientific evidence.

What FDA found

  1. The product is a drug because its website claims show it is intended to diagnose, cure, mitigate, treat, or prevent disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The product is a new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The product is misbranded because it lacks enough directions for a layperson to use it safely; diabetes treatment is not suitable for self-diagnosis or self-treatment without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Introducing the misbranded drug into interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]
  5. FTC says the company must stop claiming the product can prevent, treat, or cure diabetes without competent and reliable scientific evidence, including well-controlled human clinical studies.

    FTC Act, 15 U.S.C. § 41 et seq.

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter about specific steps taken to address the violations, including an explanation, documentation, and steps to prevent recurrence; if corrective action cannot be completed in that time, state the reason and when it will be done.

Who should pay attention

  • dietary supplement brands making disease treatment claims
  • retailers and online marketplaces selling diabetes supplements
  • consumers and caregivers managing diabetes

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk